$91.97 -0.05 (%) Biomarin Pharmaceutical Inc - NASDAQ

Jul. 27, 2016 | 01:04 PM

Headlines

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Partner Headlines

  1. Sarepta Stock Slides As FDA Sends Another Bad Signal On DMD

    IBD | Jul. 14, 2016 | 11:13AM EST
  2. Roche Holdings Definitely Not a Lumbering Giant

    GuruFocus | Jul. 11, 2016 | 13:24PM EST
  3. The FDA Just Crushed Sarepta Therapeutics' Hopes Of Releasing A Muscular Dystrophy Drug

    Benzinga | Jan. 21, 2016 | 11:23AM EST
  4. Sarepta Plummets As FDA Slams Muscular Dystrophy Drug

    IBD | Jan. 15, 2016 | 12:53PM EST
  5. BioMarin Muscular Dystrophy Drug Rejected By FDA

    IBD | Jan. 14, 2016 | 12:29PM EST
  6. BioMarin Announces Interim Analysis of INSPIRE Clinical Trial in Pompe Disease, Encouraged By Positive Trends In Trial

    Benzinga | Jan. 11, 2016 | 11:35AM EST
  7. BioMarin, Intercept hit by FDA

    IBD | Dec. 18, 2015 | 18:47PM EST
  8. BioMarin, Intercept Pharma Drugs Face FDA Delays

    IBD | Dec. 18, 2015 | 12:13PM EST
  9. BioMarin Announces That FDA Has Advised it Will Not Take Action on the Kyndrisa™ (drisapersen) New Drug Application by the PDUFA Date

    Benzinga | Dec. 18, 2015 | 08:30AM EST
  10. Pharmaceutical Stocks Hold Prominent Positions in Kyle Bass' 3rd-Quarter Activity

    GuruFocus | Nov. 27, 2015 | 16:10PM EST
  11. FDA Panel Seen As Bad For BioMarin, Good For Sarepta

    IBD | Nov. 25, 2015 | 14:34PM EST
  12. FDA Advisory Committee Discusses Clinical Data Package for BioMarin's Kyndrisa for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

    Benzinga | Nov. 24, 2015 | 19:36PM EST
  13. BioMarin Drug's Future In Doubt After FDA Panel Vote

    IBD | Nov. 24, 2015 | 18:41PM EST
  14. BIOMARIN PHARMA

    IBD | Nov. 24, 2015 | 18:33PM EST
  15. KaloBios, Valeant Lead Week's 5 Top Drug Stock Gainers

    IBD | Nov. 21, 2015 | 08:15AM EST
  16. Here's Why Sarepta Is Skyrocketing While BioMarin Is Falling

    Benzinga | Nov. 20, 2015 | 10:19AM EST
  17. Morning Market Losers

    Benzinga | Nov. 20, 2015 | 10:06AM EST
  18. Benzinga's Top #PreMarket Losers

    Benzinga | Nov. 20, 2015 | 08:17AM EST
  19. Goldman Sachs' Top 4 Smid-Cap Biotech Picks

    IBD | Nov. 18, 2015 | 15:36PM EST
  20. Benzinga's Top Initiations

    Benzinga | Nov. 18, 2015 | 09:34AM EST
  21. Biotech ETFs: Buy, Buy, Buy?

    Benzinga | Oct. 27, 2015 | 07:19AM EST
  22. Hurricane Hillary Shifts Left, Slamming More Stocks

    IBD | Oct. 22, 2015 | 15:52PM EST
  23. PTC Stock Seesaws On Muscular Dystrophy Drug Data

    IBD | Oct. 15, 2015 | 18:54PM EST
  24. BioMarin's Initial 6-Month Data From Phase 2 Study of Vosoritide (BMN 111) in Children With Achondroplasia Presented at the American Society for Bone and Mineral Research Annual 2015 Meeting

    Benzinga | Oct. 12, 2015 | 16:30PM EST
  25. Sarepta Stock Soars On New Muscular-Dystrophy Data

    IBD | Oct. 1, 2015 | 11:19AM EST
  26. BioMarin to Acquire Rights to Phenylketonuria (PKU) Franchise From Merck Serono

    Benzinga | Oct. 1, 2015 | 04:23AM EST
  27. Wednesday's After-Hours Movers: PBF Energy, BioMarin Pharmaceutical And More

    Benzinga | Sep. 30, 2015 | 16:42PM EST
  28. Stocks Rally, Will Gains Hold? Biotechs Try Second Rebound

    IBD | Sep. 30, 2015 | 10:43AM EST
  29. Benzinga's Top #PreMarket Losers

    Benzinga | Sep. 30, 2015 | 08:31AM EST
  30. Amgen And Biogen Lead Short Interest Surge In Biotechs

    Benzinga | Sep. 14, 2015 | 16:01PM EST
  31. BioMarin Announces Two Oral and 19 Poster Presentations at the Society for the Study of Inborn Errors of Metabolism 2015 Annual Meeting

    Benzinga | Aug. 31, 2015 | 08:33AM EST
  32. Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to ...

    GuruFocus | Aug. 25, 2015 | 00:02AM EST
  33. Benzinga's M&A Chatter for Monday August 24, 2015

    Benzinga | Aug. 24, 2015 | 18:44PM EST
  34. Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib, a Potent PARP Inhibitor, From BioMarin

    Benzinga | Aug. 24, 2015 | 07:00AM EST
  35. BioMarin Receives Rare Pediatric Disease Designation From FDA for Drisapersen for the Potential Treatment of Duchenne Muscular Dystrophy

    Benzinga | Aug. 19, 2015 | 16:08PM EST
  36. BioMarin Gets Price Target Hike On Pipeline Strength

    IBD | Jul. 8, 2015 | 12:12PM EST
  37. 2 DMD drugs make progress

    IBD | Jun. 29, 2015 | 18:45PM EST
  38. BioMarin, Sarepta Muscular Dystrophy Drugs Progress

    IBD | Jun. 29, 2015 | 10:18AM EST
  39. Baird Downgrades BioMarin Pharmaceutical To Neutral

    Benzinga | Jun. 19, 2015 | 10:31AM EST
  40. Benzinga's Volume Movers

    Benzinga | Jun. 19, 2015 | 10:31AM EST
  41. Benzinga's Top Downgrades

    Benzinga | Jun. 19, 2015 | 10:08AM EST
  42. Mid-Afternoon Market Update: BioMarin Pharmaceutical Jumps Following Announcement Of Positive BMN 111 Data; Jabil Circuit Shares Fall

    Benzinga | Jun. 18, 2015 | 15:32PM EST
  43. Mid-Day Market Update: Oracle Drops On Downbeat Results; Radius Health Shares Surge

    Benzinga | Jun. 18, 2015 | 13:31PM EST
  44. BioMarin Stock Hits High On Dwarfism Drug Success

    IBD | Jun. 18, 2015 | 10:36AM EST
  45. Mid-Morning Market Update: Markets Open Higher; Kroger Earnings Beat Views

    Benzinga | Jun. 18, 2015 | 10:22AM EST
  46. Benzinga's Volume Movers

    Benzinga | Jun. 18, 2015 | 10:21AM EST
  47. Morning Market Gainers

    Benzinga | Jun. 18, 2015 | 09:39AM EST
  48. Dollar, Data Boost Stock Futures; Oracle Tumbles, Taser Gains

    IBD | Jun. 18, 2015 | 09:14AM EST
  49. Benzinga's Top #PreMarket Gainers

    Benzinga | Jun. 18, 2015 | 08:12AM EST
  50. BIOMARIN PHARMA

    IBD | Jun. 17, 2015 | 18:41PM EST
Trading Center